Home / Adalimumab / United States
US ATC L04AB04 · updated 2 Nov 2026
Adalimumab shortage in United States
Is there an Adalimumab shortage in United States?
Yes. As of 2 Nov 2026, 6 Adalimumab products are reported short in United States, the first since 13 Nov 2025. No return date has been given. Main reason: not stated.
Also short in Germany, Italy, Spain, Austria, Belgium, Czechia, Sweden. All countries.
Affected products in United States
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| US | Simlandi, Kit, Kit (NDC 51759-523-21) discontinuation | Teva Pharmaceuticals USA, Inc. | 13 Nov 2025 | not given | Not stated |
| US | Hyrimoz, Injection, 40 mg/.4 mL (NDC 61314-473-64) discontinuation | Sandoz Inc. | 13 Jan 2026 | not given | Not stated |
| US | Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-36) discontinuation | Sandoz Inc. | 13 Jan 2026 | not given | Not stated |
| US | Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-68) discontinuation | Sandoz Inc. | 13 Jan 2026 | not given | Not stated |
| US | Hyrimoz, Injection, Kit (NDC 61314-517-36) discontinuation | Sandoz Inc. | 13 Jan 2026 | not given | Not stated |
| US | Hyrimoz, Injection, Kit (NDC 61314-531-64) discontinuation | Sandoz Inc. | 13 Jan 2026 | not given | Not stated |
Source
U.S. Food and Drug Administration (FDA), Drug Shortages via openFDA. Official list. Shortages the FDA lists as current, plus products to be discontinued; one row per package (NDC).